PE
CGON icon

Point72 Europe’s CG Oncology CGON Stock Holding History

Point72 Europe’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$25.2K Buy
+626
New +$18.2K ﹤0.01% 446

Other funds holding CGON

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Europe's CGON Position: Q3 2025 in Review

Point72 Europe opened a new position in CG Oncology (CGON) in Q3 2025: 626 shares worth $25.2K. The stake represents ﹤0.01% of the portfolio and ranks #446 among its holdings.

176 funds tracked by Wall St. Rank hold CGON as of Q3 2025.

  • Point72 Europe held 626 shares of CG Oncology worth $25.2K as of Q3 2025.
  • CG Oncology was a new Point72 Europe position in Q3 2025.
  • CG Oncology made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #446 holding.
  • 176 funds tracked by Wall St. Rank held CG Oncology as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.